Bosnalijek’s revenues in the first nine months of this year increased by 35% compared to the same period last year.
According to information obtained by FENA from Bosnalijek, during this period, the largest pharmaceutical company in Bosnia and Herzegovina achieved a profit of 92 million BAM, which represents an increase of 35% compared to the first nine months of 2016.
Continuous sales growth of Bosnalijek’s products on foreign markets continued this year even though revenue growth was the result of positive developments in the BiH market.
“The trend of growth of export share in the total income continued, so the revenue generated on foreign markets accounted for 64% of the total sales revenue, but also the strengthening of the position on the domestic market, with an increase of 13% in sales,” Bosnalijek announced.
Profit before taxation amounted to 5.5 million BAM.
(Source: Klix.ba)
